EXCLUSIVE INTERVIEW: Understanding Haemophilia: Insights from Dr. Honest Dewa

On World Hemophilia Day, Dr. Honest Dewa, a distinguished Specialist Physician and Clinical Haematologist, sheds light on the rare bleeding disorder known as Haemophilia. With expertise in private practice and a role as a part-time lecturer at UNAM medical school, Dr. Dewa brings valuable insights into the prevalence, causes, symptoms, and management of this condition.

Haemophilia, a rare disorder affecting clotting factors in the blood, holds a prevalence of approximately 1 in 10,000 deaths in Namibia. This translates to an estimated 200 to 300 individuals living with Haemophilia A in the country. Dr. Dewa explains that Haemophilia is hereditary, stemming from a genetic abnormality affecting the X chromosome, leading to insufficient clotting factor production.

In his discourse, Dr. Dewa delineates the three main types of Haemophilia: A, B, and C, each attributed to deficiencies in specific clotting factors. Haemophilia A results from factor VIII deficiency, Haemophilia B from factor IX deficiency, while Haemophilia C, though rare in Africa, arises from factor XI deficiency.

Recognizing the signs of Haemophilia is crucial for early diagnosis and intervention. Dr. Dewa emphasizes that the disorder often manifests through spontaneous bleeding episodes. Symptoms may include easy bruising, nosebleeds, gum bleeding, or excessive bleeding following minor injuries or surgeries, such as tooth extractions.

While Haemophilia cannot be prevented, Dr. Dewa underscores the importance of genetic counseling, particularly in families with a history of the condition. This proactive approach allows for assessing the risk of Haemophilia in offspring, enabling prompt initiation of treatment when necessary.

Regarding management, Dr. Dewa advises against certain medications and practices that may exacerbate bleeding risk in individuals with Haemophilia. Avoidance of aspirin, ibuprofen, and intramuscular injections is recommended to mitigate potential complications. Instead, incorporating foods rich in Vitamin K, such as green vegetables, may aid in blood clotting.

Dr. Dewa highlights two significant complications associated with Haemophilia: arthropathy and inhibitor development. Arthropathy refers to joint stiffness and deformities resulting from recurrent bleeding into the joints, a common occurrence in individuals with Haemophilia. Moreover, the development of inhibitors—proteins that neutralize clotting factor treatments—poses a considerable challenge, necessitating alternative therapies that may be financially burdensome for some patients.

In conclusion, Dr. Dewa’s insights provide valuable understanding and guidance for both healthcare professionals and individuals affected by Haemophilia. Through early recognition, proactive management, and ongoing research efforts, strides can be made towards improving the quality of life for those living with this rare bleeding disorder.